Xingxian Luo

机构：Peking University, Peking University People's Hospital

发表论文 39 篇 · 总被引 403 次 · h-index 13

代表论文

• The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis (2022 · The Lancet Regional Health - Western Pacific · 被引 29)
• Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022 (2023 · EClinicalMedicine · 被引 23)
• Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China (2023 · JAMA Network Open · 被引 15)
• Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China (2024 · Frontiers in Public Health · 被引 14)
• Intersection of immune signaling and cell death: The bidirectional regulatory mechanism of STING pathway and Ferroptosis (2025 · Autoimmunity Reviews · 被引 8)
• Individualized treatment with voriconazole in the Chinese population: Inflammation level as a novel marker for dose optimization (2023 · British Journal of Clinical Pharmacology · 被引 8)